报告题目: Copper-promoted oxidative C-X bond cross-coupling via boronic acids: Chan-Lam Oxidative Coupling

报告人：Dr. PATRICK Y. LAM

报告地点：无机/超分子楼二楼圆形报告厅

报告时间：2015年10月28日上午9:30 (星期三)

报告内容与人物简介: 

Patrick received his Ph.D. from the University of Rochester (Dr. Louis Friedrich) and was a postdoctoral fellow in UCLA (Prof. Mike Jung and the late Prof. Don Cram, 1987 Nobel Laureate). Patrick Lam is currently a medicinal chemistry and drug discovery consultant at Lam Drug Discovery Consulting, LLC, an Adjunct Professor at Drexel University College of Medicine and Baruch S. Blumberg Institute. He is also a Professor of Chemistry in Pennsylvania Drug Discovery Institute.

Patrick is responsible for a total of eight clinical candidates. He was the group leader/co-inventor responsible for the discovery of Eliquis?/Apixaban, a novel Factor Xa anticoagulant recently launched on the market. Eliquis? is projected by analysts to be a transformational medicine with “block-buster” sales potential. Eliquis? was recently chosen as the “Best New Medicine of 2012” by Med Ad News. He is also the inventor of the novel cyclic urea class of HIV protease inhibitors that resulted in Mozenavir/DMP450. In Phase II clinical trial, Mozenavir was shown to be as efficacious as Merck’s Crixivan.

     Patrick is internationally known as the co-discoverer of the powerful Chan-Lam Coupling Reaction. This is the copper-promoted oxidative coupling reaction for N/O-arylation with arylboronic acids and is complementary to the Nobel-prize winning Suzuki-Miyaura Coupling Reaction